Abstract:A double-blind crossover study was conducted to evaluate the antitussive effectiveness of diphenhydramine (DPH) in chornic coughs related to bronchitis, at doses of 25 and 50 mg every 4 hr for four doses. Both 25- and 50-mg doses caused a statistically and clinically significant reduction in frequency of coughs, compared to placebo. The most frequently reported side effect was drowsiness, principally at the 50-mg dose level. There was little or no apparent correlation between antitussive effectiveness and inci… Show more
“…In a double-blind crossover study, diphenhydramine, administered in four 25-mg or 50-mg doses every 4 hours, induced a statistically and clinically significant reduction in cough frequency compared with placebo. Of note, although the most frequently reported side effect was drowsiness, especially with the 50-mg dose, there was little or no apparent correlation between the antitussive effect and the incidence of sedation (Lilienfield et al, 1976). In another randomized, double-blind study of patients with cough associated with allergic rhinoconjunctivitis, treatment with 10 mg daily doses of loratadine for 4 weeks resulted in significantly improved subjective ratings of cough frequency and cough intensity compared with placebo (Ciprandi et al, 1995).…”
Section: Drugs In Current Use For the Treatment Of Coughmentioning
“…In a double-blind crossover study, diphenhydramine, administered in four 25-mg or 50-mg doses every 4 hours, induced a statistically and clinically significant reduction in cough frequency compared with placebo. Of note, although the most frequently reported side effect was drowsiness, especially with the 50-mg dose, there was little or no apparent correlation between the antitussive effect and the incidence of sedation (Lilienfield et al, 1976). In another randomized, double-blind study of patients with cough associated with allergic rhinoconjunctivitis, treatment with 10 mg daily doses of loratadine for 4 weeks resulted in significantly improved subjective ratings of cough frequency and cough intensity compared with placebo (Ciprandi et al, 1995).…”
Section: Drugs In Current Use For the Treatment Of Coughmentioning
“…There were, however, two clinical trials (level 1b) in which adult volunteers developed potentially dose-related adverse effects after receiving chronic doses of diphenhydramine. In the first, doses of 100-200 mg diphenhydramine given over 16 hours were associated with symptoms including constipation, drowsiness, and mild anticholinergic effects (87). No serious toxicity was noted in any volunteer.…”
Section: Diphenhydramine: Chronic Exposures In Patients 6 Years Of Agmentioning
“…An older antihistamine would be effective in blocking this action while a newer, peripheral antihistamine would be ineffective. At present, the only evidence supporting the concept that central histaminergic pathways are important in the production of pathologic cough in humans are studies showing efficacy of older antihistamines as antitussives [8,25]. However, these molecules can have other activities at nonhistamine receptors.…”
Section: Possible Mechanisms By Which Older Antihistamines Could Inhimentioning
confidence: 99%
“…That study supported the concept that the sedative and antitussive potentials for antihistamines are unrelated. Furthermore, Lilienfield et al [25] showed that the cough-suppressant effect of diphenhydramine in patients with lower airway disease was unrelated to the sedative effects of this drug.…”
Section: Possible Mechanisms By Which Older Antihistamines Could Inhimentioning
Older-generation H1 antihistamines are recommended in empiric protocols for the treatment of cough due to upper airway cough syndrome (UACS). Data from double-blind placebo-controlled trials that support the use of older-generation antihistamines in UACS are limited to a single study of cough due to the common cold. However, several empiric trials strongly support efficacy of older-generation antihistamines in patients with chronic cough. Data from a variety of studies support the concept that newer-generation H1 antihistamines are not useful in the treatment of cough due to UACS. The mechanism of action of older-generation H1 antihistamines has been proposed to be anticholinergic activity, but the rank order potency of these drugs as muscarinic receptor antagonists is not consistent with this hypothesis. Actions of these drugs on histamine H1 and/or nonhistaminergic receptors in the central nervous system remain a possible explanation for their effects on cough due to UACS. The effects of older H1 antihistamines may also be molecule specific, rather than attributable to the entire class of compounds. Additional studies should be performed to document the activity of these drugs in double-blind placebo-controlled trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.